Sebastian E.
- Country
- Germany
- Department
- Klinik für Internistische Onkologie
Research Overview
- Phase II Study of Total Neoadjuvant Durvalumab Plus FLOT Combination Therapy Followed by Postoperative Durvalumab in Resectable Gastroesophageal Adenocarcinoma
- Phase 3 Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancer Post-PD-1/PD-L1 Inhibitor Progression
- Phase III Randomized Study of Lurbinectedin and Atezolizumab Versus Atezolizumab in Maintenance Therapy for Extensive-Stage Small-Cell Lung Cancer
Data & Insights
Has run more than one trial at 240 of 463 partner sites.
Specializations
Non-Small Cell Lung Cancer Research
This investigator specializes in treating advanced non-small cell lung cancer (NSCLC), with particular emphasis on both squamous and nonsquamous subtypes. Their research encompasses various stages of disease progression, from resectable to metastatic cases.
- TTF-1 negative lung adenocarcinoma
- Stage IV metastatic disease
- EGFR-mutated variants
Immunotherapy Applications
The investigator focuses on novel immunotherapeutic approaches in lung cancer treatment, including studies with various immunotherapy agents such as pembrolizumab, atezolizumab, and durvalumab. Their work includes evaluation of combination therapies with conventional treatments.
- PD-1/PD-L1 inhibitor therapies
- Immunotherapy resistance patterns
- Combination immunotherapy protocols
Small Cell Lung Cancer Treatment
The investigator conducts research in limited-stage small cell lung cancer, exploring innovative treatment combinations including radiotherapy with immunotherapy. Their work encompasses both standard chemotherapy protocols and emerging therapeutic approaches.
- Concurrent chemoradiotherapy
- Limited disease management
- Multimodal treatment strategies
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.